2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2579

Rock-Mediated Pkca Nuclear Translocation Is Important in Neutrophil Netosis and UVB Induced-Skin Inflammation
Abstract Number: 2580

Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Abstract Number: 2581

Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus
Abstract Number: 2582

Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Abstract Number: 2583

Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Abstract Number: 2584

Apremilast in Patients with Lupus Rashes
Abstract Number: 2585

Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
Abstract Number: 2586

Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Abstract Number: 2587

KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Abstract Number: 2588

Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Abstract Number: 2589

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Abstract Number: 2590

Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Abstract Number: 2591

Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
Abstract Number: 2592

Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Abstract Number: 2593

Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].